Formulation of an Anti-tuberculosis Drug Delivery System PDF Download

Author: Lisa Claire Du Toit
Publisher:
ISBN:
Category :
Languages : en
Pages : 646

View

Book Description

Author: Ranjita Shegokar
Publisher: Springer Nature
ISBN: 3031141008
Category : Science
Languages : en
Pages : 335

View

Book Description
The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy. A wide variety of novel and nano-formulations using promising technologies are being explored to deliver the drug via different administration routes. This book It addresses the gap between new approaches and old treatment modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audience from wide range group like from researchers to regulatory bodies can benefit from the compiled information to find out patient needs and current research advances in the field of tuberculosis research. .

Author: Prashant Kesharwani
Publisher: Academic Press
ISBN: 0128226110
Category : Business & Economics
Languages : en
Pages : 284

View

Book Description
Nanotechnology Based Approaches for Tuberculosis Treatment discusses multiple nanotechnology-based approaches that may help overcome persisting limitations of conventional and traditional treatments. The book summarizes the types of nano drugs, their synthesis, formulation, characterization and applications, along with the most important administration routes. It also explores recent advances and achievements regarding therapeutic efficacy and provides possible future applications in this field. It will be a useful resource for investigators, pharmaceutical researchers, innovators and scientists working on technology advancements in the areas of targeted therapies, nano scale imaging systems, and diagnostic modalities in tuberculosis. Addresses the gap between nanomedicine late discovery and early development of tuberculosis therapeutics Explores tuberculosis nanomedicine standardization and characterization with newly developed treatment, diagnostic and treatment monitoring modalities Covers the field thoroughly, from the pathogenesis of tuberculosis and multi-drug resistant mycobacterium tuberculosis, to treatment approaches using nanotechnology and different nanocarriers

Author: King K. Holmes
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027

View

Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Author: Muhammad Raza Shah
Publisher: William Andrew
ISBN: 0323527302
Category : Technology & Engineering
Languages : en
Pages : 373

View

Book Description
Lipid-Based Nanocarriers for Drug Delivery and Diagnosis explores the present state of widely used lipid-based nanoparticulate delivery systems, such as solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), nanoliposomes, micelles, nanoemulsions, nanosuspensions and lipid nanotubes. The various types of lipids that can be exploited for drug delivery and their chemical composition and physicochemical characteristics are reviewed in detail, along with their characterization aspects and effects of their dimensions on drug delivery systems behavior in-vitro and in-vivo. The book covers the effective utilization of these lipids based systems for controlled and targeted delivery of potential drugs/genes for enhanced clinical efficacy. Provides the present state of widely used lipid-based nanoparticulate delivery systems Explores how lipid-based nanocarriers improve drug delivery safety Describes the nanoformulation design and the preparation methods of lipid-based nanocarriers

Author: Anthony J. Hickey
Publisher: John Wiley & Sons
ISBN: 1118943198
Category : Science
Languages : en
Pages : 456

View

Book Description
Provides a review of novel pharmaceutical approaches for Tuberculosis drugs Presents a novel perspective on tuberculosis prevention and treatment Considers the nature of disease, immunological responses, vaccine and drug delivery, disposition and response Multidisciplinary appeal, with contributions from microbiology, immunology, molecular biology, pharmaceutics, pharmacokinetics, chemical and mechanical engineering

Author: Peter R. Donald
Publisher: Karger Medical and Scientific Publishers
ISBN: 3805596278
Category : Medical
Languages : en
Pages : 262

View

Book Description
Tuberculosis (TB) remains one of the major infectious diseases of mankind although drugs for its treatment have been available for nearly 60 years. The standard short-course 6-month regimen used since about 1980 has helped to save millions of lives, but co-infection with HIV has had a devastating effect on the epidemic, and multidrug-resistant TB is a growing problem, particularly in communities with a high incidence of HIV. Following the declaration by the WHO in the early 1990s that TB was a 'global health emergency', interest in TB research and the development of new drugs has increased significantly. This volume reviews anti-TB chemotherapy with the emphasis on the actions and pharmacology of existing drugs and the development and evaluation of new agents. A close look is taken at new research regarding our existing drugs by some of the best-known specialists in the field, and historical aspects of these agents are reviewed from a modern perspective. The prospects for the introduction of new drugs and different approaches of how to assess them in adults and in children are discussed in detail. Several papers address the problems associated with drug resistance, its spread and diagnosis. Compiled by two editors from Cape Town, which has a particularly high incidence of TB and is a centre of tuberculosis research, this publication is an indispensable reference for anyone involved in the management of TB either as a researcher, clinician or administrator, and those working in drug development.

Author: World Health Organization
Publisher:
ISBN: 9789241564809
Category : Medical economics
Languages : en
Pages : 0

View

Book Description
Some volumes for 2014 includes CD-ROM for 2014 key indicators.

Author: Mariam Ibrahim
Publisher:
ISBN:
Category :
Languages : en
Pages : 188

View

Book Description
Tuberculosis (TB) is a life threatening pulmonary infection caused by Mycobacterium tuberculosis (MTB). Current treatments are complex and lengthy with patients having to take high doses of multiple drug combinations for at least 6 months. The severe side effects associated with these treatments often decreases patient compliance, thus increasing the probability of the emergence of multidrug (MDR) resistant MTB strains. Therefore, new drugs with little to no side effects and different mechanism of action to that of the existing drugs are needed to address the global TB epidemic. We discovered that SHetA2, an anticancer drug, is also active against MTB. The advantages of the pulmonary route to administer SHetA2 for TB treatment are two-fold: overcoming the poor aqueous solubility and low oral bioavailability exhibited by SHetA2, and delivering the drug directly to the lungs, the main site of TB infection. We hypothesized that pulmonary delivery of SHetA2 as dry powder aerosol can achieve local therapeutic drug concentrations that would significantly reduce the extent of infection. Using Quality by Design approaches, we designed, optimized and manufactured three different formulations of SHetA2 MPs, SHetA2 alone, SHetA2 PLGA and SHetA2 mannitol microparticles (MPs), to maximize the drug dose, target alveolar macrophages and increase drug solubility, respectively. The three SHetA2 MPs had optimum particle sizes and distributions for alveolar deposition and were chemically stable. Manufacture by spray drying physically transformed the crystalline structure of SHetA2 to the amorphous form, which significantly increased its solubility. All SHetA2 MPs were efficiently dispersed with the Aerolizer® dry powder inhaler, as indicated by the high respirable fraction after aerosolization into a next generation impactor. Moreover, the respirable fraction of SHetA2 MP dissolved much faster, and to a greater extent, than the unprocessed drug. All SHetA2 MPs formulations were highly uptaken by macrophages, demonstrating their potential to kill intracellular MTB. An in vitro efficacy study using infected macrophages showed moderate efficacy of SHetA2 MPs against intracellular MTB with no apparent side effects on the macrophages. Our mechanistic studies designed to gain insight into the 6 mechanism by which SHetA2 kills MTB identified MTB DnaK as a protein target for SHetA2 in MTB. Our preliminary results suggest that the interference of SHetA2 in the binding of MTB DnaK to RV1636 stress proteins could be such a mechanism, in a manner similar to the way SHetA2 disrupts mortalin/p53 and p66shc binding for its anticancer activity.

Author: World Health Organization
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 60

View

Book Description